BostonGene, a leader in AI-driven molecular and immune profiling that accelerates drug development and personalizes patient care, today announced that four abstracts have been selected for ...

Catalytic conversion of waste CO2 into value-added fuels and chemicals offers unprecedented opportunities for both ...

Integrated DNA Technologies' new xGen™ Hybridization and Wash v3 Kit is poised to revolutionize targeted next generation sequencing (NGS) workflows. The user-friendly workflow enables NGS cancer ...

Enhertu (fam-trastuzumab deruxtecan-nxki) is currently indicated as a second-line therapy for HER2-positive metastatic breast cancer.